valcyte在国内上市了吗？

Is Valganciclovir Hydrochloride Tablets () available in China? On August 20, 2006, Shanghai Roche Pharmaceutical Co., Ltd. held a press conference for the launch of valganciclovir hydrochloride tablets (valcyte) in China in Dalian. The meeting invited clinical and pharmacological experts from Roche's headquarters and well-known scholars in my country's transplant community to give speeches. It also invited reporters and editors from many domestic newspapers and medical professional media. More than 200 clinicians from the transplant community from across the country attended the meeting. 

Cytomegalovirus infection is a common complication after organ transplantation, with an incidence rate as high as 50%. The pain caused by organ rejection, cardiovascular disease, post-transplantation diabetes and related treatments has seriously affected the quality of life of patients. Valcyte is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. Just taking 2 valganciclovir hydrochloride tablets (valcyte) per day can effectively prevent and treat CMV infection, avoid the direct and indirect harm caused by CMV infection, and significantly improve the patient's quality of life and long-term survival rate. 

Professor Tang Xiaoda, chairman of the Chinese Dialysis and Transplantation Research Association, told reporters: "Patients should not only focus on before the operation, but also on how to maintain the survival of the transplanted organ and improve the overall quality of life after the operation. In particular, sufficient attention should be paid to the prevention of cytomegalovirus infection in patients at risk." 

So far, valganciclovir hydrochloride tablets (valcyte) are on the market in major countries around the world. By collecting price data of valganciclovir hydrochloride tablets (valcyte) in different countries, we will find that Roche’s valganciclovir hydrochloride tablets (valcyte) have the lowest price in the “World Pharmacy” India, which benefits from the local people-friendly medical policies.